{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:50:17Z","timestamp":1789908617706,"version":"4.0.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1001826","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T17:51:38Z","timestamp":1431453098000},"page":"e1001826","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs"],"prefix":"10.1371","volume":"12","author":[{"given":"Patricia","family":"McGettigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Roderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushikesh","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson M.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"ref1","unstructured":"Harris G (2014 Apr 14) Medicines made in India set off safety worries. New York Times. http:\/\/www.nytimes.com\/2014\/02\/15\/world\/asia\/medicines-made-in-india-set-off-safety-worries.html<\/ext-link>. Accessed 30 March 2015."},{"key":"ref2","unstructured":"European Medicines Agency (2015 Jan 23) GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/01\/news_detail_002256.jsp&mid=WC0b01ac058004d5c1<\/ext-link>. Accessed 30 March 2015."},{"key":"ref3","unstructured":"Porecha M (2014 Apr 22) Vietnam shows the door to 45 Indian pharma companies. DNA (Diligent Media Corporation). http:\/\/www.dnaindia.com\/mumbai\/report-vietnam-shows-the-door-to-45-indian-pharma-companies-1980761<\/ext-link>. Accessed 30 March 2015."},{"key":"ref4","unstructured":"Ministry of Health and Family Welfare (2003) Report of the expert committee on a comprehensive examination of drug regulatory issues, including the problem of spurious drugs. http:\/\/planningcommission.nic.in\/reports\/genrep\/health\/Final_Report_mashelkar.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref5","unstructured":"Community Development Medicinal Unit, Health Action International Asia Pacific (2010 Dec 15) Report on research project: \u2018fixed-dose combination in India, inception\u2014marketing\u2014a study\u2019. http:\/\/www.cdmuindia.org\/Pdf-files\/Final-report-IFDCs.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref6","unstructured":"Department-Related Standing Committee on Health and Family Welfare (2012 May) 59th report on the functioning of the Central Drugs Standard Control Organization (CDSCO). New Delhi: Parliament of India. http:\/\/164.100.47.5\/newcommittee\/reports\/englishcommittees\/committee%20on%20health%20and%20family%20welfare\/59.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref7","first-page":"1852","article-title":"Drug regulation in India\u2014the time is ripe for change","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"ref8","unstructured":"World Health Organization (2005) Annex 5: guidelines for registration of fixed dose combination medicinal products. WHO Technical Report Series, No. 929. http:\/\/apps.who.int\/medicinedocs\/documents\/s19979en\/s19979en.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref9","first-page":"158","article-title":"Rationality of fixed dose combinations: an Indian scenario","volume":"1","author":"N Jain","year":"2009","journal-title":"Pharma Res"},{"key":"ref10","unstructured":"Medicines and Healthcare Products Regulatory Agency (2012) Summary of product characteristics: chlorpromazine 100mg tablets. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1407476358070.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref11","unstructured":"Medicines and Healthcare Products Regulatory Agency (2012) Summary of product characteristics: stelazine 5 mg tablets or trifluoperazine 5 mg tablets. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1389947107511.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref12","unstructured":"National Institute for Health and Care Excellence (2015) British National Formulary. Available (UK only): http:\/\/www.evidence.nhs.uk\/formulary\/bnf\/current<\/ext-link>. Accessed 30 March 2015."},{"key":"ref13","unstructured":"Singh GN (2013 Jul 5) To: all state\/UT drug controllers. Subject: approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from the office of DCG(I)\u2014regarding. F. No. 4-01\/2013-DC (Misc13-PSC). http:\/\/www.cdsco.nic.in\/writereaddata\/Approval_of_the_safety_and%20efficacy_FDC.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref14","year":"2013"},{"key":"ref15","unstructured":"Government of India Ministry of Health and Family Welfare (2003) The Drugs and Cosmetics Act and Rules. http:\/\/www.emergogroup.com\/sites\/default\/files\/file\/india-drugs-and-cosmetics-act-1940-act-no-23.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref16","unstructured":"Central Drugs Standard Control Organization (2013) Fixed dose combinations approved by DCG(I) since 1961 till December, 2013. http:\/\/www.cdsco.nic.in\/writereaddata\/FDC_approved_dcgi%281%29_2013.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref17","unstructured":"Medicines and Healthcare Products Regulatory Agency (2015) Medicines information: SPC & PILs. http:\/\/www.mhra.gov.uk\/Safetyinformation\/Medicinesinformation\/SPCandPILs\/index.htm<\/ext-link>. Accessed 30 March 2015."},{"key":"ref18","unstructured":"US Food and Drug Administration (2015) Orange book: approved drug products with therapeutic equivalence evaluations. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/docs\/tempai.cfm?firstRec=101<\/ext-link>. Accessed 30 March 2015."},{"key":"ref19","unstructured":"(2015) Monthly Index of Medical Specialties. http:\/\/www.mims.co.uk<\/ext-link>. Accessed 30 March 2015."},{"key":"ref20","unstructured":"AIOCD AWACS (2015) Products and offering: PharmaTrac. http:\/\/www.aiocdawacs.com\/ProductDetail.aspx<\/ext-link>. Accessed 30 March 2015."},{"key":"ref21","unstructured":"Lang TA, Altman DG (2013) Biostatistical reporting for articles reported in biomedical journals: the \u201cStatistical Analyses and Methods in the Published LITERATURE\u201d or the SAMPL guidelines. Equator Network. http:\/\/www.equator-network.org\/wp-content\/uploads\/2013\/07\/SAMPL-Guidelines-6-27-13.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref22","year":"2014"},{"key":"ref23","unstructured":"European Medicines Agency (2011 Jun 23) European Medicines Agency concludes review of systemic nimesulide-containing medicines. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/06\/news_detail_001285.jsp&mid=WC0b01ac058004d5c1<\/ext-link>. Accessed 7 April 2015."},{"key":"ref24","unstructured":"European Medicines Agency (2014 Jan 17) European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Thiocolchicoside-containing_medicines\/WC500155447.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref25","unstructured":"European Medicines Agency (2009 Jun 25) European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2009\/11\/news_detail_000074.jsp&mid=WC0b01ac058004d5c1<\/ext-link>. Accessed 30 March 2015."},{"key":"ref26","unstructured":"United Nations Department of Economic and Social Affairs (2005) Consolidated list of products whose consumption and\/or sale have been banned, withdrawn, severely restricted or not approved by governments, twelfth issue. http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js16780e\/<\/ext-link>. Accessed 30 March 2015."},{"key":"ref27","unstructured":"Das S (2014 Jul 25) Lundbeck to seek legal recourse after health ministry bans Deanxit again. Economic Times. http:\/\/articles.economictimes.indiatimes.com\/2014-07-25\/news\/52026547_1_lundbeck-deanxit-franxit<\/ext-link>. Accessed 30 March 2015."},{"key":"ref28","article-title":"UNESCO series on journalism education","author":"ML Hunter","year":"2012"},{"key":"ref29","unstructured":"World Health Organization (2005) Thioridazine withdrawn due to poor benefit\/risk profile. WHO Pharmaceuticals Newsletter 2005, No 01. http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js8116e\/1.7.html<\/ext-link>. Accessed 30 March 2015."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/gerona\/62.10.1172","article-title":"Medication as a risk factor for falls: critical systematic review","volume":"62","author":"S Hartikainen","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/0976-500X.103684","article-title":"Ethics of expert opinion and the observations of the department-related parliamentary standing committee on the CDSCO","volume":"3","author":"A Jesani","year":"2012","journal-title":"J Pharmacol Pharmacother"},{"key":"ref32","unstructured":"BioSpectrum Bureau (2013 Aug 19) India approved 26 drugs without clinical trials. http:\/\/www.biospectrumasia.com\/biospectrum\/news\/193708\/india-approved-26-drugs-clinical-trials#.Uv9z0oXrCw8<\/ext-link>. Accessed 30 March 2015."},{"key":"ref33","unstructured":"Datapharm (2015) eMC [database]. http:\/\/www.medicines.org.uk\/emc\/<\/ext-link>. Accessed 30 March 2015."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00002018-200528070-00008","article-title":"The pharmacovigilance system in India","volume":"28","author":"N Kshirsagar","year":"2005","journal-title":"Drug Saf"},{"key":"ref35","first-page":"15","article-title":"Current problems and future aspects of pharmacovigilance in India","volume":"2","author":"AK Gosh","year":"2011","journal-title":"Int J Pharma Bio Sci"},{"key":"ref36","year":"2013"},{"key":"ref37","unstructured":"(2015) CIMS India [database]. http:\/\/www.cimsasia.com\/<\/ext-link>. Accessed 30 March 2015."},{"key":"ref38","unstructured":"Health and Social Care Information Centre (2013) Prescription cost analysis: England 2012. http:\/\/www.hscic.gov.uk\/catalogue\/PUB10610\/pres-cost-anal-eng-2012a-rep.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref39","unstructured":"Selvaraj S (2013 Jul 14) Another bitter pill for patients. The Hindu. http:\/\/www.thehindu.com\/opinion\/op-ed\/another-bitter-pill-for-patients\/article4912747.ece<\/ext-link>. Accessed 30 March 2015."},{"key":"ref40","unstructured":"Pradhan R (2013 Nov 13) Medicines prices: DPCO loopholes will deny cheaper essential drugs. Moneylife. http:\/\/www.moneylife.in\/article\/effect-of-drug-prices-control-order-dpco-2013-on-medicines\/35249.html<\/ext-link>. Accessed 30 March 2015."},{"key":"ref41","unstructured":"Shetty S, Modi R (2013) India Pharma Inc.: changing landscape of the Indian pharma industry. Pricewaterhouse Coopers; Confederation of Indian Industry. http:\/\/www.pwc.in\/assets\/pdfs\/publications\/2013\/changing-landscape-of-the-indian-pharma-industry.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref42","unstructured":"Singh GN (2013 Jan 15) To: all state\/UTs drugs controllers. Subject: approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from the office of DCG(I)\u2014regarding. F. No. 4-01\/2013-DC (Misc13-PSC). http:\/\/www.cdsco.nic.in\/writereaddata\/Approval_of_the_safety_and_efficacy_of_FDC.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref43","unstructured":"Chaudhury RR (2013 Jul) Report of the Prof. Rajnit Roy Chaudhury Expert Committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs. http:\/\/www.indiaenvironmentportal.org.in\/files\/file\/clinical%20trials1.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref44","unstructured":"Central Drugs Standard Control Organization (2013 Jun) Policy guidelines for the approval of fixed dose combinations (FDCs) in India. http:\/\/www.mohfw.nic.in\/WriteReadData\/l892s\/6404452866Kokate%20Report.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref45","unstructured":"Singh GN (2014 Jun 5) To: all state\/UTs drugs controllers. Subject: approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from the office of DCG(I)\u2014regarding. F. No. 4-01\/2013-DC (Misc13-PSC). http:\/\/www.cdsco.nic.in\/writereaddata\/approvalfdc.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref46","unstructured":"Veerramani SV (2014 Jul 25) To: Shri Lov Verma, IAS. Subject: fixed dose combinations (FDCs). Indian Drug Manufacturers Association. http:\/\/www.idma-assn.org\/pdf\/25-07-2014_Letter_to_Shri_Lov_Verma_Health_Secretary_on_FDCs.pdf<\/ext-link>. Accessed 30 March 2015."},{"issue":"33","key":"ref47","first-page":"15","article-title":"Need for a new drugs bill","volume":"XLIX","author":"P Roderick","year":"2014","journal-title":"Econ Polit Wkly"},{"key":"ref48","unstructured":"(2013) The Drugs and Cosmetics (Amendment) Bill of 2013. Government of India. http:\/\/www.prsindia.org\/uploads\/media\/Drugs%20and%20Cosmetics\/drugs%20and%20cosmetics%20bill.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref49","unstructured":"(2014 Dec 31) The Drugs and Cosmetics (Amendment) Bill of 2015 [draft]. Department of Health and Family Welfare. http:\/\/www.cdsco.nic.in\/writereaddata\/D&%20C%20AMMENDMENT%20BILL%281%29.pdf<\/ext-link>. Accessed 30 March 2015."},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMp1210007","article-title":"Reform, regulation, and pharmaceuticals: the Kefauver-Harris amendments at 50","volume":"367","author":"JA Greene","year":"2012","journal-title":"N Engl J Med"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1001826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:14:57Z","timestamp":1589012097000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1001826"}},"subtitle":[],"editor":[{"given":"Aaron S","family":"Kesselheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1001826","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}